titaprutug (TWP-102)
/ TheraWisdom Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 04, 2024
Initial findings of safety and efficacy from the multicenter, open-label, phase I study of Titaprutug (TWP-102), an anti-CTLA-4 antibody, in the patients(pts) with advanced malignant tumors
(SITC 2024)
- P1 | "Background Titaprutug (TWP-102) is a novel recombinant anti CTLA-4 monoclonal antibody, known as an IgG1/κ immunoglobulin. The special molecular design significantly reduces the toxicity compared with Ipilimumab, prolongs the treatment cycles obviously. Further tolerability and antitumor activity will be evaluated in pts with advanced malignancies."
Clinical • IO biomarker • Metastases • P1 data • Breast Cancer • Cervical Cancer • Malignant Pleural Mesothelioma • Melanoma • Mesothelioma • Oncology • Solid Tumor • CD80 • CD86
October 04, 2024
Initial findings of safety and efficacy from the multicenter, open-label, phase I study of Titaprutug (TWP-102), an anti-CTLA-4 antibody, in the patients(pts) with advanced malignant tumors
(SITC 2024)
- P1 | "Background Titaprutug (TWP-102) is a novel recombinant anti CTLA-4 monoclonal antibody, known as an IgG1/κ immunoglobulin. The special molecular design significantly reduces the toxicity compared with Ipilimumab, prolongs the treatment cycles obviously. Further tolerability and antitumor activity will be evaluated in pts with advanced malignancies."
Clinical • IO biomarker • Metastases • P1 data • Breast Cancer • Cervical Cancer • Malignant Pleural Mesothelioma • Melanoma • Mesothelioma • Oncology • Solid Tumor • CD80 • CD86
1 to 2
Of
2
Go to page
1